Sepsis induces a biphasic immune response: an initial hyperinflammatory phase followed by a prolonged immunosuppressive state characterized by impaired host defense. Identifying reliable biomarkers to detect this late-phase immune paralysis is essential for guiding targeted therapies. This study examines the dynamics of viral reactivation across multiple virus families—herpesviruses (CMV, EBV, HSV, HHV-6), polyomaviruses (BK, JC), and anellovirus TTV—as potential real-time indicators of immune dysfunction in critically ill patients.
We analyzed serial blood and urine samples from 560 septic patients, 161 non-septic ICU controls, and 164 healthy individuals using quantitative PCR. Viral DNA was assessed in whole blood and plasma, with BK and JC measured in urine. The cumulative detection rates were compared across groups and correlated with clinical outcomes including secondary infections, ICU length of stay, severity scores (APACHE-II, SOFA), and 90-day mortality.
Results revealed a striking increase in viral reactivation among septic patients. CMV was detected in 24.2%, EBV in 53.2%, HSV in 14.1%, HHV-6 in 10.4%, and TTV in 77.5% of cases. Over 42% had two or more concurrent viral infections. In contrast, viral DNAemia was rare in non-septic ICU patients (38.5%) and absent in healthy controls (0%). The time course of reactivation showed rapid onset: TTV reached 50% detection within 3–6 days of sepsis onset, while herpesviruses peaked between days 5 and 13.
High-level viremia—exceeding 10⁴ copies/mL—was observed in a subset of patients, particularly for CMV and EBV. These levels are clinically significant, as they are associated with increased risk of tissue injury and poor outcomes in transplant recipients.Furan-2,4-dicarboxylic acid Epigenetics Notably, patients with detectable CMV in plasma had significantly higher 90-day mortality (p = 0.Axitinib Biological Activity 05).PMID:35160088 Those with EBV viremia in blood showed improved survival—a paradoxical finding possibly linked to early immune activation—but this benefit diminished with rising viral load.
Clinically, viral reactivation strongly predicted secondary infections. Patients with CMV or EBV viremia were more likely to develop fungal infections and opportunistic bacterial pathogens such as Acinetobacter, Stenotrophomonas, and Enterococcus. ICU length of stay was significantly longer in viremic patients, and APACHE-II and SOFA scores were markedly higher, indicating greater physiological compromise.
TTV emerged as a particularly useful biomarker. Its high prevalence (77.5%) and elevated levels in septic patients reflect ongoing immune dysregulation. Unlike herpesviruses, which may reactivate due to stress or inflammation, TTV replicates continuously at low levels; thus, its viral load serves as a sensitive surrogate for overall immune competence. Higher TTV loads, especially in the upper quartile, trended toward increased mortality, reinforcing its role as a marker of profound immunosuppression.
These findings demonstrate that viral reactivation is not incidental but a hallmark of functional immune deficiency in sepsis. Serial monitoring of viral DNA levels—particularly for CMV, EBV, and TTV—could provide a practical, objective method to track immune status in real time. Such monitoring could help identify patients who would benefit from immunoadjuvant therapies like GM-CSF or interferon-γ, which may improve survival if administered during the immunosuppressive phase. Future studies should validate these results in larger cohorts and integrate viral load tracking into clinical decision-making for sepsis management.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com